Our Business Sample Clauses

Our Business. 2.1. easyMarkets is a pioneer online trading group that was founded in 2001, and has revolutionized currency, commodities, indices and options trading in over 160 countries ever since. We are pioneers in developing online trading as a consumer product, and one of the leaders in the market with customized technology and personal service tailored to all levels of knowledge and experience traders, accessible from any location. We develop easy and user-friendly online trading platforms for execution-only transactions in the over-the-counter spot foreign exchange, forward foreign exchange, CFD commodities CFD Index markets, CFD Shares and CFD Cryptocurrencies (“Financial Products”) and options trading. We further provide you with real-time tradable BID-ASK tradable prices by collecting and aggregating information sourced through, independent price providers, relevant exchanges and interbank participants who normally supply liquidity and information to the global FX and Futures market and distributes the real time BID-ASK tradable prices to you via our proprietary and 3rd party trading platforms. 2.2. Our proprietary platforms include: • Web Trading Platform for desktop devices; • Web Trading Platform for mobile devices; • iOS Application (Compatible with iPhone™, iPad™); • Android Application. 2.3. Our non-proprietary (third party) platforms include: • MetaTrader 4 (MT4) – proprietary rights of Metaquotes Software Inc.; • MetaTrader 4 (MT4 mobile version)– proprietary rights of Metaquotes Software Inc.; • MetaTrader 5 (MT5) – proprietary rights of Metaquotes Software Inc.; • MetaTrader 5 (MT5 mobile version)– proprietary rights of Metaquotes Software Inc.; • TradingView Platform- proprietary rights of TradingView Inc. 2.4. We also provide you with the following services: 2.5. easyMarkets will offer you access to TradingView social network. TradingView will be provided to various jurisdictions as the Company may deem necessary from time to time. You hereby acknowledge, agree and confirm that certain trading conditions via TradingView shall differ in comparison with the trading conditions available in our proprietary platform. Such trading conditions, include but is not limited to: (a) Market orders opened manually or closed manually by the Client via TradingView, are subject to slippage, (b) Vanilla Options, Forward deals, easyTrade and dealCancellation are not available in TradingView Platform.

Our Business. 3.1 The Company is a pioneer online trading group that was founded in 2015, and has revolutionized currency, commodities, indices and options trading and investment in over 130 countries ever since. We are pioneers in developing online trading as a consumer product, and one of the leaders in the market with customized technology and personal service tailored to all levels of knowledge and experience traders and investors ("you"), accessible from any location. We develop easy and user friendly online trading platforms for execution-only transactions in the over-the-counter spot foreign exchange, forward foreign exchange, CFD commodities and CFD Index markets ("Financial Products") and options trading. We further provide you with real time tradable BID-ASK tradable prices by collecting and aggregating information sourced through, independent price providers, relevant exchanges and interbank participants who normally supply liquidity and information to the global FX and Futures market and distributes the real time BID-ASK tradable prices to you via our proprietary and 3rd party trading platforms. We also offer clients of all experience levels investment opportunities to be sustainably successful in the online trading of forex, commodities, energies, cryptocurrencies and indices. 3.2 Our proprietary platforms include: • Web Trading Platform • MT4 integration (Direct account management) • MT5 integration (Direct account management) • High Yield Investment Platform • Cryptocurrency Mining Pools 3.3 We also provide you with the following services: • Dealing via the Company Chat Service • Account Management Service • Subscription Trading Service

Our Business. The Company is a pioneer online trading group that was founded in 2013, and has revolutionized currency, commodities, indices and options trading in over 165 countries ever since. We are pioneers in developing online trading as a consumer product, and one of the leaders in the market with customized technology and personal service tailored to all levels of knowledge and experience traders ("you"), accessible from any location. We develop easy and user-friendly online trading platforms for execution-only transactions in the over-the-counter spot foreign exchange, forward foreign exchange, CFD commodities and CFD Index markets ("Financial Products") and options trading. We further provide you with real time tradable BUY-SELL tradable prices by collecting and aggregating information sourced through, independent price providers, relevant exchanges and interbank participants who normally supply liquidity and information to the global FX and Futures market and distributes the real time BUY-SELL tradable prices to you via our proprietary and 3rd party trading platforms. Our proprietary platforms include: ▪ Web Trading Platform We also provide you with the following services. ▪ Direct Phone Dealing with our professional sales client managers ▪ Dealing via the Company Chat Service

Our Business. We are a clinical-stage immuno-oncology company focused on discovering and developing highly targeted cancer immunotherapies. Our product candidates represent an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called innate immune cells (Natural Killer cells, or NK cells, and macrophages) and T cells. Leveraging our fit-for-purpose ROCK® platform, we develop proprietary, next-generation bispecific and trispecific antibodies, so-called innate cell engagers (ICE®), which are designed to direct innate immune cells and establish a bridge to cancer cells. Our innate cell engagers have the ability to bring innate immune cells into the proximity of tumor cells and trigger an activation cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture with four binding domains, our innate cell engagers bind to their targets with high affinity. Different dosing schemes are being explored to allow for improved exposure in heavily pretreated patient populations. Based on their mechanism of action as well as the preclinical and clinical data we have generated to date, we believe that our product candidates as monotherapy and / or in combination, may ultimately improve response rates, clinical outcomes and survival in cancer patients, and could eventually become a cornerstone of modern targeted oncology care. Building on our leadership in the innate cell engager space, we are also developing novel antibody formats with the potential to tailor innate cell-engaging therapy to different indications and settings. Affimed was founded in 2000 based on technology developed by the group led by Xxxxxxxxx Xxxxxx Xxxxxx at Deutsches Krebsforschungszentrum (DKFZ), the German Cancer Research Center, in Heidelberg, Germany. Focusing our efforts on antibodies that specifically bind to innate cells through CD16A, a key activating receptor, we have built a clinical and preclinical pipeline of innate cell-engaging bispecific antibodies designed to activate both innate and adaptive immunity. Compared to a variety of T cell-engaging technologies, our innate cell engagers appear to have a better safety profile and have the potential to achieve more potent and deeper immune responses potentially through enhancing crosstalk of innate and adaptive immunity. The safety profiles of our molecules make them suitable f...

Our Business. The following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus, including the documents incorporated by reference, which are described under “Incorporation of Certain Information by Reference” and “Where You Can Find More Information” in this prospectus. You should also carefully consider the matters discussed in the section titled “Risk Factors” in this prospectus and in other periodic reports incorporated by reference herein.

Our Business. This summary highlights selected information contained elsewhere in this prospectus that we consider important. This summary does not contain all of the information you should consider before investing in our securities. You should read this summary together with the entire prospectus, including the risks related to our business, our industry, investing in our ordinary shares and our location in Israel, that we describe under “Risk Factors” and our consolidated financial statements and the related notes before making an investment in our securities.

Our Business. 3.1 The Company is a Forex Brokerage that was founded in 2020, and has revolutionized currency, commodities, indices and options trading in over 160 countries ever since. We are pioneers in developing online trading as a consumer product, and one of the leaders in the market with customized technology and personal service tailored to all levels of knowledge and experience traders ("you"), accessible from any location. We develop easy and user friendly online trading platforms for execution-only transactions in the over-the-counter spot foreign exchange, forward foreign exchange, CFD commodities and CFD Index markets ("Financial Products") and options trading. We further provide you with real time tradable BID-ASK tradable prices by collecting and aggregating information sourced through, independent price providers, relevant exchanges and interbank participants who normally supply liquidity and information to the global FX and Futures market and distributes the real time BID-ASK tradable prices to you via our proprietary and 3rd party trading platforms. 3.2 Our non-proprietary (third party) platforms include: • Metatrader 5 (proprietary rights of Metaquotes Software Inc.) • Metatrader 5 Mobile - (proprietary rights of Metaquotes Software Inc.) 3.3 We also provide you with the following services: • Direct Phone Dealing with our professional sales client managers

Our Business. 3.1 The Company is a pioneer online trading group that was founded in 2018, and has revolutionized currency, commodities, indices trading in over 160 countries ever since. We are pioneers in developing online trading as a consumer product, and one of the leaders in the market with customized technology and personal service tailored to all levels of knowledge and experience traders ("you"), accessible from any location. We develop easy and user friendly online trading platforms for execution-only transactions in the over -the -counter spot foreign exchange , forward foreign exchange). We further provide you with real time tradable BID-ASK tradable prices by collecting and aggregating information sourced through , independent price providers , relevant exchanges and interbank participants who normally supply liquidity and information to the global FX market and distributes the real time BID-ASK tradable prices to you via our proprietary and 3rd party trading platforms. 3.2 Our proprietary platforms include: • Web Trading Platform 3.3 Our non-proprietary (third party) platforms include: • Metatrader 5 (proprietary rights of Metaquotes Software Inc.) • Metatrader 5 Mobile - (proprietary rights of Metaquotes Software Inc.) • ORE Platform (proprietary rights of ORE Technologies Ltd)

Our Business. We are a global leader in stored electrical energy solutions and one of the world’s largest manufacturers of lead acid batteries used in transportation, motive power, network power and military applications. The market for transportation batteries is divided between sales to original-equipment customers and aftermarket automotive manufacturers. Our industrial energy segments supply both motive power and network power applications. Our many brands include Exide®, Absolyte®, Centra™, Classic®, DETA®, Fulmen®, GNB™, Liberator™, Marathon®, Sonnenschein® and Tudor®. We are a Delaware corporation organized in 1966 to succeed to the business of a New Jersey corporation founded in 1888. Our principal executive offices are located at 10000 Xxxxxxxxx Xxxxxxx, Xxxxxxxx 000, Xxxxxxxxxx, Xxxxxxx 00000. Our phone number at that location is (000) 000-0000. More comprehensive information about us and our products is available through our Internet website at hxxx://xxx.xxxxx.xxx. Except for the documents incorporated by reference in this Offer to Amend, the information and other content contained on our website, or other sites linked to it, are not incorporated by reference into this Offer to Amend and you should not consider any of that information or content to be part of this Offer to Amend.

Our Business. We are an end-to-end commercial biopharmaceutical and specialty immunoglobulin company dedicated to manufacturing, marketing and developing specialty plasma- derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. We currently have three products with FDA approval, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (“IVIG”) product indicated for the treatment of Primary Humoral Immunodeficiency (“PI”), also known as Primary Immunodeficiency Disease (“PIDD”), and for which we received FDA approval on May 9, 2019 for the commercial re-launch of the product and commenced the re-launch in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), previously referred to as RI-002, an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (“HBsAg”) and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of S. pneumonia. We manufacture our products at an FDA-licensed, 400,000-liter annual capacity plasma fractionation and purification facility located in Boca Raton, Florida (the “Boca Facility”). Based on current production yields, we believe this facility has the potential to produce quantities of our immune globulin (“IG”) products capable of generating more than $250 million in annual revenue as we ramp-up production over the next three to five years. Our products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases. Through our ADMA BioCenters subsidiary, we currently operate as an FDA-approved source ...